Auf dem Weg zum nachhaltigen Stadtviertel

Wie die nachhaltige Stadt der Zukunft aussehen könnte, zeigt der Stadtteil „Scharnhauser Park“ in Ostfildern bei Stuttgart. In diesem Quartier versuchen Wissenschaftler und Investoren, einen ganzen Stadtteil so optimal wie möglich nach nachhaltigen Gesichtspunkten zu gestalten

Logik und Logikprogrammierung: Band 2: Aufgaben und Lösungen

https://corescholar.libraries.wright.edu/books/1065/thumbnail.jp

Stakeholder-supported Research on the Food-Water-Energy Nexus with three International Case Studies

The projected increasing population in cities and metropolitan regions results in higher demands of resources, i.e., food, water, and energy (FAO 2018), that are essential for human well-being, poverty reduction, and sustainable development(Hülsmann and Ardakanian 2018).There are clear interactions between water, food, and energy that may result in synergies or trade-offs between different sectors or interest groups. To address the issue,the international project IN-SOURCE models and analyses the Food-Water-Energy Nexus (FWE Nexus) in three case study regions of Germany, Austria and the United States of America. Due to the complexity of the nexus issue, stakeholders have been involved actively in the research process, whose valuable output would strongly support the decision-making processes. This paper gives an overview of the methods, case studies, and stakeholder involvement of the whole project. With the novel methods, stakeholder-oriented process, and case studies' representativity, IN-SOURCE serves as a benchmark for future FWE researches

Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures

Aggressive pheochromocytomas and paragangliomas (PPGLs) are difficult to treat, and molecular targeting is being increasingly considered, but with variable results. This study investigates established and novel molecular-targeted drugs and chemotherapeutic agents for the treatment of PPGLs in human primary cultures and murine cell line spheroids. In PPGLs from 33 patients, including 7 metastatic PPGLs, we identified germline or somatic driver-mutations in 79% of cases, allowing us to assess potential differences in drug responsivity between pseudohypoxia-associated cluster 1- (n=10) and kinase signaling-associated cluster 2-related (n=14) PPGL primary cultures. Single anti-cancer drugs were either more effective in cluster 1 (cabozantinib, selpercatinib, 5-FU) or similarly effective in both clusters (everolimus, sunitinib, alpelisib, trametinib, niraparib, entinostat, gemcitabine, AR-A014418, high-dose zoledronic acid). High-dose estrogen and low-dose zoledronic acid were the only single substances more effective in cluster 2. Neither cluster 1- nor cluster 2-related patient primary cultures responded to HIF-2α inhibitors, temozolomide, dabrafenib, or octreotide. We showed particular efficacy of targeted combination treatments (cabozantinib/everolimus, alpelisib/everolimus, alpelisib/trametinib) in both clusters, with higher efficacy of some targeted combinations in cluster 2 and overall synergistic effects (cabozantinib/everolimus, alpelisib/trametinib) or synergistic effects in cluster 2 (alpelisib/everolimus). Cabozantinib/everolimus combination therapy, gemcitabine, and high-dose zoledronic acid appear to be promising treatment options with particularly high efficacy in SDHB-mutant and metastatic tumors. In conclusion, only minor differences regarding drug responsivity were found between cluster 1 and cluster 2: some single anti-cancer drugs were more effective in cluster 1 and some targeted combination treatments were more effective in cluster 2

Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures

: Aggressive pheochromocytomas and paragangliomas (PPGLs) are difficult to treat, and molecular targeting is being increasingly considered, but with variable results. This study investigates established and novel molecular-targeted drugs and chemotherapeutic agents for the treatment of PPGLs in human primary cultures and murine cell line spheroids. In PPGLs from 33 patients, including 7 metastatic PPGLs, we identified germline or somatic driver-mutations in 79% of cases, allowing us to assess potential differences in drug responsivity between pseudohypoxia-associated cluster 1- (n=10) and kinase signaling-associated cluster 2-related (n=14) PPGL primary cultures. Single anti-cancer drugs were either more effective in cluster 1 (cabozantinib, selpercatinib, 5-FU) or similarly effective in both clusters (everolimus, sunitinib, alpelisib, trametinib, niraparib, entinostat, gemcitabine, AR-A014418, high-dose zoledronic acid). High-dose estrogen and low-dose zoledronic acid were the only single substances more effective in cluster 2. Neither cluster 1- nor cluster 2-related patient primary cultures responded to HIF-2α inhibitors, temozolomide, dabrafenib, or octreotide. We showed particular efficacy of targeted combination treatments (cabozantinib/everolimus, alpelisib/everolimus, alpelisib/trametinib) in both clusters, with higher efficacy of some targeted combinations in cluster 2 and overall synergistic effects (cabozantinib/everolimus, alpelisib/trametinib) or synergistic effects in cluster 2 (alpelisib/everolimus). Cabozantinib/everolimus combination therapy, gemcitabine, and high-dose zoledronic acid appear to be promising treatment options with particularly high efficacy in SDHB-mutant and metastatic tumors. In conclusion, only minor differences regarding drug responsivity were found between cluster 1 and cluster 2: some single anti-cancer drugs were more effective in cluster 1 and some targeted combination treatments were more effective in cluster 2